![]() |
市场调查报告书
商品编码
2008823
内视镜再处理市场报告:按产品、製程、最终用户和地区划分(2026-2034 年)Endoscope Reprocessing Market Report by Product, Process, End User, and Region 2026-2034 |
||||||
2025年,全球内视镜器械再处理市场规模达24.7亿美元。展望未来,IMARC集团预测,到2034年,该市场规模将达到42.3亿美元,2026年至2034年的复合年增长率(CAGR)为5.97%。推动该市场成长的主要因素是微创手术需求的不断增长以及感染控制日益严格的法规。此外,再处理设备的快速技术进步、患者安全意识的提高以及内视镜检查数量的激增也促进了市场成长。
对微创手术的需求日益增长
微创手术日益普及是内视镜器械再处理市场成长的主要驱动力。这些利用内视镜进行的手术相比传统手术具有许多优势,例如恢復时间更短、感染风险更低、术后疼痛更轻。根据美国国家生物技术资讯中心(NCBI)发布的数据,美国每年约进行1770万例胃肠内视镜检查,占所有内视镜检查的68%。胃肠内视镜检查后的整体感染率为0.2%,但某些手术的感染率较高。具体而言,ERCP(逆行性造影)的感染率为0.8%,除ERCP以外的上消化道内视镜检查的感染率为0.123%,下消化道内视镜检查的感染率为0.073%。因此,内视镜检查的频率不断增加,对有效再处理解决方案的需求也随之增加,以确保内视镜的安全性和耐用性。
提出严格的感染管制条例
产业报告显示,软式内视镜消毒不彻底与医院感染(HAI)密切相关,对病患和医疗系统带来沉重负担。医院感染是患者最常通报的不利事件,在欧洲的发生率高达6.5%。手术部位感染占所有医院感染的18.3%,会对病患的生活品质产生负面影响,增加发病率和死亡率。此外,手术部位感染也会对医疗系统带来巨大的经济负担。在德国,手术部位感染平均可使住院时间延长17.9天,并使每位患者额外支出22,905欧元。因此,世界各国政府和医疗机构正在实施严格的法规来预防医院感染。为了遵守这些法规并避免处罚,医疗机构正在投资先进的内视镜消毒系统。这确保了内视镜得到彻底的清洁、消毒和灭菌,从而降低医院感染的风险并提高病患安全。
再处理设备的技术进步
技术进步正显着推动内视镜再处理市场的成长。自动化再处理系统、高性能消毒剂和先进的追踪系统等创新技术提高了再处理流程的效率和可靠性。这些技术是内视镜再处理解决方案普及和推广的关键因素,因为它们确保内视镜始终保持高标准的清洁度,降低人为错误的风险,并简化医疗工作流程。例如,2023年1月,领先的柔性机器人器械开发商Agilis Robotics完成了其第二次使用自主研发的内视镜手术机器人进行的动物活体试验。结果显示,该机器人系统在有效性、准确性和安全性方面均取得了令人鼓舞的成果。因此,预计机器人技术在内镜手术中的日益普及将导致手术数量的增加,从而推动市场成长。
The global endoscope reprocessing market size reached USD 2.47 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 4.23 Billion by 2034, exhibiting a growth rate (CAGR) of 5.97% during 2026-2034. The market is primarily being driven by the rising demand for minimally invasive surgeries, and the implementation of stringent regulations on infection control. Additionally, rapid technological advancements in reprocessing equipment, growing awareness about patient safety, and the surging prevalence of endoscopy procedures are further contributing to the market growth.
Increasing Demand for Minimally Invasive Surgeries
The rising preference for minimally invasive surgeries is acting as a major driver for the endoscope reprocessing market growth. These procedures, which use endoscopes, offer benefits such as reduced recovery time, lower risk of infection, and less postoperative pain compared to traditional surgeries. According to the data published on National Center for Biotechnology, approximately 17.7 million gastrointestinal (GI) endoscopic procedures are performed annually in the United States, accounting for 68% of all endoscopic procedures. The composite infection rate following GI endoscopic procedures was 0.2%, with higher rates for specific procedures: 0.8% for ERCP, 0.123% for non-ERCP upper GI endoscopies, and 0.073% for lower GI endoscopies. As a result, the frequency of endoscopic procedures is increasing, leading to a higher demand for effective reprocessing solutions to ensure the safety and longevity of endoscopes.
Implementation of Stringent Infection Control Regulations
As per industry reports, failures in reprocessing flexible endoscopes are associated with hospital-acquired infections (HAIs), which place a significant burden on patients and healthcare systems. HAIs are the most reported adverse events affecting patients, with a prevalence of 6.5% across Europe. Surgical site infections, comprising 18.3% of all HAIs, negatively affect patient quality of life and increase morbidity and mortality rates. They also contribute to a significant financial burden on healthcare systems. In Germany, surgical site infections can lead to an average hospital stay extension of 17.9 days and an additional healthcare cost of €22,905 per patient. As a result, governments and healthcare organizations worldwide are implementing stringent regulations to prevent hospital-acquired infections (HAIs). To comply with these regulations and avoid penalties, healthcare facilities are investing in advanced endoscope reprocessing systems. This ensures that endoscopes are thoroughly cleaned, disinfected, and sterilized, thereby reducing the risk of HAIs and improving patient safety.
Technological Advancements in Reprocessing Equipment
Advancements in technologies are significantly driving the endoscope reprocessing market growth. Innovations, such as automated reprocessing machines, enhanced disinfectants, and sophisticated tracking systems, have improved the efficiency and reliability of the reprocessing process. These technologies ensure that endoscopes are consistently cleaned to high standards, reduce the risk of human error, and streamline the workflow in healthcare facilities, making them a critical factor in the adoption and expansion of endoscope reprocessing solutions. For instance, in January 2023, Agilis Robotics, a leading developer of flexible robotic instruments, completed its second round of live animal testing with its proprietary robot for endoscopic surgery. The results demonstrated promising outcomes in terms of efficacy, accuracy, and safety of the robotic system. Consequently, the increasing integration of robotics in endoscopic surgery is expected to boost the number of procedures performed, thereby driving market growth.
High-level disinfectants and test strips account for the majority of the market share
High-level disinfectants and test strips are enhancing the endoscope reprocessing market value due to their effectiveness and efficiency in ensuring patient safety. These disinfectants are specifically designed to eliminate a broad spectrum of pathogens, including highly resistant organisms such as Mycobacterium tuberculosis and Clostridium difficile. Their fast-acting nature and compatibility with automated reprocessors make them a preferred choice in busy healthcare settings. Test strips play a crucial role in validating the efficacy of the disinfection process, providing immediate confirmation that the minimum recommended concentration of the disinfectant is met, thus ensuring compliance with safety standards and reducing the risk of infections. For instance, RAPICIDE high-level disinfectant is a glutaraldehyde-based, fast-acting, reusable solution for flexible endoscopes in automated reprocessors, requiring no mixing or activation. It reprocesses heat-sensitive, semi-critical medical devices in systems like the DSD-201, inactivating pathogens such as TB, C-diff, and CRE with a 5-minute contact time at 95°F (35°C). The disinfectant enhances efficiency with only two rinses needed. RAPICIDE(TM) Test Strips confirm the minimum recommended concentration of glutaraldehyde, requiring a 3-second dip and a 75-second read time. This example illustrates how specific products drive the demand for high-level disinfectants and test strips in the market, thereby increasing the endoscope reprocessing market value.
Automated cleaning holds the largest share of the industry
Automated cleaning dominates the endoscope reprocessing market due to its ability to ensure consistent and high-level disinfection, reducing the risk of human error associated with manual cleaning. Automated systems, such as automated endoscope reprocessors (AERs), provide standardized, efficient, and effective cleaning and disinfecting processes, which are critical for patient safety. These systems enhance workflow efficiency within healthcare facilities by minimizing both the time and labor involved in reprocessing endoscopes. Additionally, automated cleaning systems are specifically designed to accommodate the intricate designs of modern endoscopes, ensuring thorough decontamination and adherence to stringent regulatory standards. As part of the endoscope reprocessing market forecast, it is expected that the growing adoption of automated cleaning solutions will continue to shape the market, driven by advancements in technology and the increasing demand for reliable and efficient reprocessing methods.
For instance, in March 2023, PENTAX Medical, a division of the HOYA Group, was awarded the CE mark for its innovative automated pre-cleaning solution, the AquaTYPHOON. Developed in collaboration with PlasmaBiotics, this device offers a robust alternative to the traditional manual pre-cleaning step in endoscope reprocessing, effectively addressing the hygiene challenges healthcare providers encounter in daily clinical practice.
Hospitals and clinics represent the leading market segment
The endoscope reprocessing market research report highlights that hospitals and clinics are the dominant segment in the market, attributed to the large volume of endoscopic procedures conducted within these facilities. According to industry reports, the number of bariatric surgery procedures in Ireland reached 219 in 2023, significantly surpassing the revised target of 200 set by the Health Service Executive (HSE). This marked a substantial increase from the 109 procedures performed in 2022. These surgeries were conducted at three HSE sites: St Vincent's University Hospital in Dublin, St Michael's Hospital in Dun Laoghaire, and University Hospital Galway. Additionally, University Hospital Galway alone performed 49 surgeries in 2023, up from 19 in the previous year.
These facilities require stringent infection control measures to prevent hospital-acquired infections, making effective reprocessing essential. The increasing prevalence of minimally invasive surgeries, which frequently utilize endoscopes, further drives demand. Additionally, regulatory requirements and guidelines mandate rigorous reprocessing protocols to ensure patient safety. The combination of high procedural volume, regulatory compliance, and the critical need for infection prevention establishes hospitals and clinics as the primary market segment for endoscope reprocessing.
North America leads the market, accounting for the largest endoscope reprocessing market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for endoscope reprocessing.
North America's dominance in the endoscope reprocessing market can be attributed to its advanced healthcare infrastructure, increasing prevalence of chronic diseases, stringent regulatory standards, and high frequency of endoscopic procedures. For example, a 2024 article by the American Society of Anesthesiologists indicates that approximately 6.1 million upper endoscopies are performed annually in the U.S. Furthermore, the CDC reports that around 129 million Americans suffer from at least one major chronic condition, significantly driving the need for endoscope reprocessing solutions. As endoscopic procedures become more common for both diagnostic and therapeutic purposes, the endoscope reprocessing market outlook reflects a growing demand for effective reprocessing technologies. The region's healthcare systems, equipped with sophisticated technologies and protocols, ensure effective endoscope reprocessing to prevent infections. Additionally, heightened awareness of infection control among healthcare providers and patients, along with continuous technological advancements and a focus on patient safety, further solidify North America's leading position in the market.